1 Key Insights
2 Executive Summary
3 SWOT Analysis
4 wAIHA Market Overview at a Glance
4.1 Market Share (%) Distribution of wAIHA in 2017
4.2 Market Share (%) Distribution of wAIHA in 2030
5 Disease Background and Overview
5.1 Introduction
5.2 Types
5.3 Causes
5.4 Signs and Symptoms
5.5 Pathophysiology
5.6 Manifestations
5.7 Diagnosis Immunohematological assessment of patients with AIHA DAT-negative AIHA
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 KOL Views
6.3 7MM Total Prevalent Patient Population of wAIHA
6.4 Assumptions and Rationale: 7MM
7 Country Wise-Epidemiology of wAIHA
7.1 The United States
7.1.1 Total Prevalent Cases of AIHA in the United States
7.1.2 Diagnosed Prevalence of wAIHA in the United States
7.1.3 Type-specific Prevalence of wAIHA in the United States
7.1.4 Gender-specific Prevalence of wAIHA in the United States
7.2 EU5
7.2.1 Germany
7.2.1.1 Total Prevalent Cases of AIHA in Germany
7.2.1.2 Diagnosed Prevalence of wAIHA in Germany
7.2.1.3 Type-specific Prevalence of wAIHA in Germany
7.2.1.4 Gender-specific Prevalence of wAIHA in Germany
7.2.2 France
7.2.2.1 Total Prevalent Cases of AIHA in France
7.2.2.2 Diagnosed Prevalence of wAIHA in France
7.2.2.3 Type-specific Prevalence of wAIHA in France
7.2.2.4 Gender-specific Prevalence of wAIHA in France
7.2.3 Italy
7.2.3.1 Total Prevalent Cases of AIHA in Italy
7.2.3.2 Diagnosed Prevalence of wAIHA in Italy
7.2.3.3 Type-specific Prevalence of wAIHA in Italy
7.2.3.4 Gender-specific Prevalence of wAIHA in Italy
7.2.4 Spain
7.2.4.1 Total Prevalent Cases of AIHA in Spain
7.2.4.2 Diagnosed Prevalence of wAIHA in Spain
7.2.4.3 Type-specific Prevalence of wAIHA in Spain
7.2.4.4 Gender-specific Prevalence of wAIHA in Spain
7.2.5 The United Kingdom
7.2.5.1 Total Prevalent Cases of AIHA in the UK
7.2.5.2 Diagnosed Prevalence of wAIHA in the UK
7.2.5.3 Type-specific Prevalence of wAIHA in the UK
7.2.5.4 Gender-specific Prevalence of wAIHA in the UK
7.3 Japan
7.3.1 Total Prevalent Cases of AIHA in Japan
7.3.2 Diagnosed Prevalence of wAIHA in Japan
7.3.3 Type-specific Prevalence of wAIHA in Japan
7.3.4 Gender-specific Prevalence of wAIHA in Japan
8 Treatment and Management of wAIHA
8.1 Sequential approach to treatment options for w-AIHA and common dosing regimens
8.1.1 First-line therapy
8.1.1.1 Corticosteroids
8.1.2 Second-line therapy
8.1.2.1 Splenectomy
8.1.2.2 Rituximab
8.1.2.3 Immunosuppressive drugs
8.1.2.4 Other Options
8.2 British Guidelines for WAIHA treatment
9 Case Study
10 Patient Journey
11 Unmet Needs
12 Appendix
12.1 Report Methodology
13 DelveInsight Capabilities
14 Disclaimer
15 About DelveInsight
Table 1: Classification of w-AIHATable 2: Prevalent Patient Population of wAIHA in 7MM (2017-2030)
Table 3: Total Prevalent Cases of AIHA in the United States (2017-2030)
Table 4: Diagnosed Prevalence of wAIHA in the United States (2017-2030)
Table 5: Type-specific Prevalence of wAIHA in the United States (2017-2030)
Table 6: Gender-specific Prevalence of wAIHA in the United States (2017-2030)
Table 7: Total Prevalent Cases of AIHA in Germany (2017-2030)
Table 8: Diagnosed Prevalence of wAIHA in Germany (2017-2030)
Table 9: Type-specific Prevalence of wAIHA in Germany (2017-2030)
Table 10: Gender-specific Prevalence of wAIHA in Germany (2017-2030)
Table 11: Total Prevalent Cases of AIHA in France (2017-2030)
Table 12: Diagnosed Prevalence of wAIHA in France (2017-2030)
Table 13: Type-specific Prevalence of wAIHA in France (2017-2030)
Table 14: Gender-specific Prevalence of wAIHA in France (2017-2030)
Table 15: Total Prevalent Cases of AIHA in Italy (2017-2030)
Table 16: Diagnosed Prevalence of wAIHA in Italy (2017-2030)
Table 17: Type-specific Prevalence of wAIHA in Italy (2017-2030)
Table 18: Gender-specific Prevalence of wAIHA in Italy (2017-2030)
Table 19: Total Prevalent Cases of AIHA in Spain (2017-2030)
Table 20: Diagnosed Prevalence of wAIHA in Spain (2017-2030)
Table 21: Type-specific Prevalence of wAIHA in Spain (2017-2030)
Table 22: Gender-specific Prevalence of wAIHA in Spain (2017-2030)
Table 23: Total Prevalent Cases of AIHA in the United Kingdom (2017-2030)
Table 24: Diagnosed Prevalence of wAIHA in the United Kingdom (2017-2030)
Table 25: Type-specific Prevalence of wAIHA in the United Kingdom (2017-2030)
Table 26: Gender-specific Prevalence of wAIHA in the United Kingdom (2017-2030)
Table 27: Total Prevalent Cases of AIHA in Japan (2017-2030)
Table 28: Diagnosed Prevalence of wAIHA in Japan (2017-2030)
Table 29: Type-specific Prevalence of wAIHA in Japan (2017-2030)
Table 30: Gender-specific Prevalence of wAIHA in Japan (2017-2030)
Table 31: Treatment Flow
Figure 1: SWOT Analysis of WAIHA
Figure 2 : Mechanisms of hemolysis in warm antibody autoimmune hemolytic anemia
Figure 3: Clinical-serologic associations with the direct Coombs test
Figure 4: Prevalent Patient Population of wAIHA in 7MM (2017-2030)
Figure 5: Total Prevalent Cases of AIHA in the United States (2017-2030)
Figure 6: Diagnosed Prevalence of wAIHA in the United States (2017-2030)
Figure 7: Type-specific Prevalence of wAIHA in the United States (2017-2030)
Figure 8: Gender-specific Prevalence of wAIHA in the United States (2017-2030)
Figure 9: Total Prevalent Cases of AIHA in Germany (2017-2030)
Figure 10: Diagnosed Prevalence of wAIHA in Germany (2017-2030)
Figure 11: Type-specific Prevalence of wAIHA in Germany (2017-2030)
Figure 12: Gender-specific Prevalence of wAIHA in Germany (2017-2030)
Figure 13: Total Prevalent Cases of AIHA in France (2017-2030)
Figure 14:Diagnosed Prevalence of wAIHA in France (2017-2030)
Figure 15: Type-specific Prevalence of wAIHA in France (2017-2030)
Figure 16: Gender-specific Prevalence of wAIHA in France (2017-2030)
Figure 17: Total Prevalent Cases of AIHA in Italy (2017-2030)
Figure 18: Diagnosed Prevalence of wAIHA in Italy (2017-2030)
Figure 19: Type-specific Prevalence of wAIHA in Italy (2017-2030)
Figure 20: Gender-specific Prevalence of wAIHA in Italy (2017-2030)
Figure 21: Total Prevalent Cases of AIHA in Spain (2017-2030)
Figure 22: Diagnosed Prevalence of wAIHA in Spain (2017-2030)
Figure 23: Type-specific Prevalence of wAIHA in Spain (2017-2030)
Figure 24: Gender-specific Prevalence of wAIHA in Spain (2017-2030)
Figure 25: Total Prevalent Cases of AIHA in the UK (2017-2030)
Figure 26: Diagnosed Prevalence of wAIHA in the UK (2017-2030)
Figure 27: Type-specific Prevalence of wAIHA in the UK (2017-2030)
Figure 28: Gender-specific Prevalence of wAIHA in the UK (2017-2030)
Figure 29: Total Prevalent Cases of AIHA in Japan (2017-2030)
Figure 30: Diagnosed Prevalence of wAIHA in Japan (2017-2030)
Figure 31: Type-specific Prevalence of wAIHA in Japan (2017-2030)
Figure 32: Gender-specific Prevalence of wAIHA in Japan (2017-2030)
Figure 33: Treatment algorithm for warm AIHA in adults
Figure 34: Mechanisms of hemolysis in warm antibody autoimmune hemolytic anemia
Figure 35: Unmet Needs of wAIHA
Figure 51: Market Drivers
Figure 52: Market Barriers
【免責事項】
https://www.marketreport.jp/reports-disclaimer